Blockchain Registration Transaction Record

Scinai Extends PinCell Option, Seeks €12M EU Grant for Skin Disease Therapy

Scinai Immunotherapeutics extends its option to acquire PinCell and applies for a €12M EU grant to fund PC111, a therapy for pemphigus vulgaris and SJS/TEN skin diseases.

This development matters because it represents a critical financing and strategic milestone for a potential treatment addressing severe, underserved medical conditions. Pemphigus vulgaris and SJS/TEN are devastating disorders with limited treatment options; SJS/TEN, in particular, has a high mortality rate and often leaves survivors with long-term complications. The €12 million in non-dilutive funding sought from the European SMART Path program is significant—it would fund 80% of the R&D for PC111 without requiring equity dilution or repayment, preserving shareholder value while de-risking the path to clinical trials. For patients, this news signals progress toward a targeted therapy that could address the underlying immune dysfunction in these diseases, potentially offering a more effective and safer alternative to current broad immunosuppressants. For the biotech investment community, it demonstrates Scinai's execution capability in navigating complex regulatory funding pathways and structuring strategic acquisitions (PinCell) to bolster its pipeline. Success in securing this grant and advancing PC111 could validate Scinai's research approach, attract partnership interest for its NanoAb platform, and ultimately bring a novel treatment closer to patients who currently face dire prognoses.